CYTK - サイトキネティクス （Cytokinetics Incorporated） サイトキネティクスCYTKのチャート
CYTKの企業情報
| symbol | CYTK |
|---|---|
| 会社名 | Cytokinetics Inc （サイトキネティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 サイトカイネティックス(Cytokinetics Incorporated)は後期バイオ医薬品会社である。同社は筋肉のパフォーマンスが損害あるいは低下などの衰弱性疾患の潜在的治療法としてのファースト・イン・クラス筋肉活性化因子の発見、開発、商業化などを行う。重病治療のために筋肉機能を調節する小分子治療法の発見と開発を中心とする。同社の臨床階段の薬品候補はtirasemtiv、CK-2127107とomecamtiv mecarbilを含む。同社は筋萎縮性側索硬化症（ALS）の治療のためのティラセミチブ薬候補を開発する。脊髄性筋萎縮、慢性閉塞性肺疾患およびALSの潜在的治療薬としてCK-2127107を開発する。Omecamtiv mecarbilは心不全の治療するための心筋ミオシンアクチベーターである。 サイトキネティクスは、米国の医薬品会社。心不全治療を適応とする医薬品薬候補の発見、開発、商業化に従事。主に、筋萎縮性側索硬化症に対する｢Tirasemtiv(正式名称：CK-2017357)｣の臨床試験に焦点を当てている。本社はカリフォルニア州サウスサンフランシスコ。 |
| 本社所在地 | 280 East Grand Avenue South San Francisco CA 94080 USA |
| 代表者氏名 | Leonard Patrick Gage レナード・パトリック・ゲージ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-624-3000 |
| 設立年月日 | 35643 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2004年 |
| 従業員数 | 137人 |
| url | www.cytokinetics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cytk |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -112.14400 |
| 終値（lastsale） | 8.23 |
| 時価総額（marketcap） | 449588415.31 |
| 時価総額 | 時価総額（百万ドル） 429.92230 |
| 売上高 | 売上高（百万ドル） 17.64500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 230.34630 |
| 当期純利益 | 当期純利益（百万ドル） -130.64600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cytokinetics Inc. revenues increased 59% to $11.5M. Net loss increased 5% to $57.8M. Revenues reflect Revenue Sales of Goods_Serv increase from $818K to $8.3M. Higher net loss reflects Research and development increase of 12% to $43.7M (expense) Non-cash interest expense on liability r increase of 41% to $8.5M (expense) General and administrative increase of 5% to $17.3M (expense). |
CYTKのテクニカル分析
CYTKのニュース
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics 2021/05/03 18:48:46 Benzinga
Cytokinetics Inc (NASDAQ: CYTK ) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and develop skeletal sarcomere activators for diseases associated with muscle weakness. Astellas had extended the research pact initially set to expire on December 31 last year, through March of this year. But last week, Astellas gave written notice that it wants out of the pact altogether and gives up “all licenses and other rights” granted through the … Full story available on Benzinga.com
Mizuho Securities Stick to Their Buy Rating for Cytokinetics By Investing.com 2021/04/13 08:15:01 Investing.com
Mizuho Securities Stick to Their Buy Rating for Cytokinetics
Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells 10,000 Shares of Stock 2021/03/19 23:32:53 Watchlist News
Cytokinetics, Incorporated (NASDAQ:CYTK) Director L Patrick Gage sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 19th. The stock was sold at an average price of $24.45, for a total transaction of $244,500.00. Following the sale, the director now directly owns 31,762 shares in the company, valued at approximately […]
Cytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference 2021/01/06 21:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President…
Morgan Stanley Stick to Their Buy Rating for Cytokinetics 2020/12/16 20:35:38 Investing.com
Morgan Stanley Stick to Their Buy Rating for Cytokinetics
Mizuho Securities Stick to Their Buy Rating for Cytokinetics By Investing.com 2021/04/13 08:15:01 Investing.com
Mizuho Securities Stick to Their Buy Rating for Cytokinetics
Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells 10,000 Shares of Stock 2021/03/19 23:32:53 Watchlist News
Cytokinetics, Incorporated (NASDAQ:CYTK) Director L Patrick Gage sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 19th. The stock was sold at an average price of $24.45, for a total transaction of $244,500.00. Following the sale, the director now directly owns 31,762 shares in the company, valued at approximately […]
Cytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference 2021/01/06 21:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President…